Study on the effects of drospirenone and ethinylestradiol in inducing follicular development in patients with premature ovarian insufficiency
10.3760/cma.j.cn101441-20230906-00110
- VernacularTitle:屈螺酮炔雌醇在早发性卵巢功能不全患者诱导卵泡发育作用的研究
- Author:
Kexin SHEN
1
;
Wendan ZHANG
;
Yunhai CHUAI
;
Honghong JIANG
;
Chunlan SONG
;
Zhuolin RUAN
;
Mingming SHU
;
Shun YAO
;
Wei ZHONG
;
Wei SHANG
Author Information
1. 中国人民解放军总医院第七医学中心妇产医学部生殖医学科，北京 100700
- Publication Type:Journal Article
- Keywords:
Primary ovarian insufficiency;
Oral contraceptive;
Drug induction;
Follicular development
- From:
Chinese Journal of Reproduction and Contraception
2024;44(5):516-521
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of drospirenone and ethinylestradiol in the treatment of ovulation induction in patients with premature ovarian insufficiency (POI).Methods:A randomized controlled clinical study analyzed the clinical data of 130 POI patients who underwent assisted reproductive treatment at the Department of Reproductive Medicine, Department of Obstetrics and Gynecology, the Seventh Medical Center and Department of Obstetrics and Gynecology, the Sixth Medical Center of Chinese people's Liberation Army General Hospital from December 2021 to November 2022. The subject-centered randomization method was used to conceal the allocation, and there was no blinding. The patients in experimental group was given drospirenone and ethinylestradiol as pretreatment, while control group was not treated. The main observation indicator of the follicle recovery growth rate and the secondary observation indicators of estradiol and follicle-stimulating hormone (FSH) levels before and after pretreatment, the number of eggs retrieved, the proportion of eggs retrieved, and other embryo laboratory-related indicators were compared between the two groups.Results:The recovery rate of follicular growth in the experimental group was significantly higher than that in control group, and the difference was statistically significant [50.77% (33/65) vs. 15.38% (10/65), P<0.001, rate difference =35.38%, 95% CI: 19.44%-48.98%]. The levels of FSH [17.70 (8.15, 27.00) U/L] decreased significantly and estradiol [24.00 (15.00, 90.47) ng/L] increased significantly in the experimental group after preconditioning with spironolone ethinylestradiol compared with those before preconditioning [30.30 (25.95, 48.05) U/L, P<0.001; 15.00 (15.00, 24.00) ng/L, P<0.001], the differences were statistically significant. Conclusion:The spironolone ethinylestradiol can effectively inhibit the level of FSH and increase the level of estradiol in patients with POI, and increase the probability of ovarian growth and development during ovulation induction therapy.
